Predict your next investment

Venture Capital
epvc.com

See what CB Insights has to offer

Investments

267

Portfolio Exits

70

Funds

7

About Enterprise Partners Venture Capital

Enterprise Partners Venture Capital is a La Jolla, California-based early stage venture capital firm. It will opportunistically look at later stage companies and buyout opportunities as well. In terms of industry focus, Enterprise Partners generally prefers investment in the healthcare, energy and technology sectors with a focus on industries such as digital media, wireless, digital home technologies, and energy and materials amongst others. Geographically, the firm prefers to invest between $3 and $10 million in portfolio companies but will invest as little as $300,000 in a seed round. Generally, the firm prefers to take a Board seat and often seeks to be a lead investor.

Enterprise Partners Venture Capital Headquarter Location

2223 Avenida de la Playa Suite 300

La Jolla, California, 92037,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Enterprise Partners Venture Capital

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Enterprise Partners Venture Capital in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Latest Enterprise Partners Venture Capital News

Celladon Corporation Announces In-License Of Stem Cell Factor Development Program

Jul 21, 2014

Celladon (CLDN) Jumps: Stock Up 11.5% - Tale of the Tape Celladon Corporation (Nasdaq: CLDN ), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation today announced an exclusive, global license from Enterprise Partners Venture Capital for gene therapy applications of the membrane-bound form of the Stem Cell Factor gene (mSCF) for treatment of cardiac ischemia. Stem Cell Factor is a critical cytokine which contributes to cell migration, proliferation, and survival of cardiac stem cells. Researchers at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai have successfully tested mSCF gene therapy to reverse heart damage following myocardial infarction in animal models. These results were recently published in Circulation Research and are available on the Company's website www.celladon.com . "mSCF gene therapy promoted a regenerative response in damaged hearts similar to that observed with stem cell therapy and may be one of the first non-cell therapies to increase cardiac muscle precursors in the heart," said the study's senior investigator Roger J. Hajjar, M.D., Director of the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai and the Arthur & Janet C. Ross Professor of Medicine at Mount Sinai. "We are excited by the future possibility of testing this gene therapy in patients. " Celladon plans to commence further preclinical work, building on available data from Mount Sinai in myocardial infarction. "We believe mSCF gene therapy has the potential to be a powerful therapeutic approach, harnessing the potency of stem cell therapy without the associated complications of developing cells as products," said Krisztina Zsebo, Ph.D., Chief Executive Officer of Celladon. "We're delighted that this promising program will be taken forward by Celladon, leveraging our extensive gene therapy research and product development experience. Our initial focus will be to generate clinically acceptable gene therapy vectors © 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Enterprise Partners Venture Capital Investments

267 Investments

Enterprise Partners Venture Capital has made 267 investments. Their latest investment was in Scoperta as part of their Series C - II on October 10, 2014.

CBI Logo

Enterprise Partners Venture Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/3/2014

Series C - II

Scoperta

$5.5M

No

2

11/27/2013

Debt - II

Verdezyne

$6M

Yes

1

10/25/2013

Debt - VIII

Celladon

$1.09M

No

1

7/23/2013

Series C

Subscribe to see more

$99M

Subscribe to see more

10

2/22/2013

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/3/2014

11/27/2013

10/25/2013

7/23/2013

2/22/2013

Round

Series C - II

Debt - II

Debt - VIII

Series C

Series B - II

Company

Scoperta

Verdezyne

Celladon

Subscribe to see more

Subscribe to see more

Amount

$5.5M

$6M

$1.09M

$99M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

1

1

10

10

Enterprise Partners Venture Capital Portfolio Exits

70 Portfolio Exits

Enterprise Partners Venture Capital has 70 portfolio exits. Their latest portfolio exit was Stamps.com on October 06, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/6/2021

Take Private

$99M

6

5/8/2019

Acquired

$99M

1

11/9/2018

Acq - P2P

$99M

4

7/2/2018

IPO

Subscribe to see more

$99M

Subscribe to see more

0

8/23/2017

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/6/2021

5/8/2019

11/9/2018

7/2/2018

8/23/2017

Exit

Take Private

Acquired

Acq - P2P

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

6

1

4

0

10

Enterprise Partners Venture Capital Acquisitions

9 Acquisitions

Enterprise Partners Venture Capital acquired 9 companies. Their latest acquisition was Muze on May 17, 2005.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

5/17/2005

$99M

Acq - Fin

9/1/1995

Subscribe to see more

$99M

Subscribe to see more

10

8/2/1993

Series A

Subscribe to see more

$99M

$99M

Subscribe to see more

10

6/26/1992

Series A

Subscribe to see more

$99M

$99M

Subscribe to see more

10

3/16/1992

Growth Equity

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

5/17/2005

9/1/1995

8/2/1993

6/26/1992

3/16/1992

Investment Stage

Series A

Series A

Growth Equity

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$99M

$99M

$99M

Note

Acq - Fin

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

10

10

10

10

Enterprise Partners Venture Capital Fund History

7 Fund Histories

Enterprise Partners Venture Capital has 7 funds, including Enterprise Partners VI LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

7/16/2001

Enterprise Partners VI LP

Early-Stage Venture Capital

Closed

$350M

1

11/5/1999

Enterprise Partners V LP

Subscribe to see more

Subscribe to see more

$99M

10

5/30/1997

Enterprise Partners IV LP

Subscribe to see more

Subscribe to see more

$99M

10

1/1/1993

Enterprise Partners III LP

Subscribe to see more

Subscribe to see more

$99M

10

1/1/1989

Enterprise Partners II LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

7/16/2001

11/5/1999

5/30/1997

1/1/1993

1/1/1989

Fund

Enterprise Partners VI LP

Enterprise Partners V LP

Enterprise Partners IV LP

Enterprise Partners III LP

Enterprise Partners II LP

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$350M

$99M

$99M

$99M

$99M

Sources

1

10

10

10

10

Enterprise Partners Venture Capital Team

11 Team Members

Enterprise Partners Venture Capital has 11 team members, including current Controller, Yrsa Nordlicht.

Name

Work History

Title

Status

James H. Berglund

Founder

Current

Yrsa Nordlicht

Controller

Current

Carlton J. Eibl

Managing Director

Current

Drew Senyei

Managing Director

Current

Andy Chedrick

Chief Financial Officer

Former

Name

James H. Berglund

Yrsa Nordlicht

Carlton J. Eibl

Drew Senyei

Andy Chedrick

Work History

Title

Founder

Controller

Managing Director

Managing Director

Chief Financial Officer

Status

Current

Current

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.